NovaBay Pharmaceuticals, Inc.
AMEX: NBY0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange Arca
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael Kazley
- Employees
- 13
- Headquarters
- EmeryVille, United States
- IPO year
- 2007
- Market cap
- $39.1M
- Website
- https://novabay.com
Loading NBY…
Loading profile data…Frequently asked questions about NBY
What does NovaBay Pharmaceuticals, Inc. (NBY) do?
NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, an...
Where does NBY trade?
NovaBay Pharmaceuticals, Inc. (NBY) trades on the New York Stock Exchange Arca.
What sector is NBY in?
NovaBay Pharmaceuticals, Inc. (NBY) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NovaBay Pharmaceuticals, Inc.?
Michael Kazley is the chief executive officer of NovaBay Pharmaceuticals, Inc. (NBY).
Where is NovaBay Pharmaceuticals, Inc. headquartered?
NovaBay Pharmaceuticals, Inc. is headquartered in United States.
Does NBY pay a dividend?
Yes — NovaBay Pharmaceuticals, Inc. (NBY) paid a trailing twelve-month dividend of USD 0.80 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did NBY go public?
NovaBay Pharmaceuticals, Inc. (NBY) completed its initial public offering in 2007.